<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03023306</url>
  </required_header>
  <id_info>
    <org_study_id>IRB No 11139, Date 01-31-2017</org_study_id>
    <nct_id>NCT03023306</nct_id>
  </id_info>
  <brief_title>Preemptive Versus Preventive Antiemetics</brief_title>
  <official_title>Effectiveness of Preemptive Versus Preventive Antiemetic Treatment in Patients Undergoing Thyroidectomy. A Randomized Double Blind Trial.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Athens</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Athens</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Female patients aged between 20 and 70 years, ASA physical status I-II, and scheduled for
      thyroidectomy under general anaesthesia will be enrolled in the study.

      Patients will be randomized to the preemptive group to receive an antiemetic regime the day
      before surgery or to the intraoperative group to receive the same antiemetic drugs in the
      same doses intraoperatively.

      In the operating room standard monitoring and a standardized anesthetic technique will be
      implemented in all patients. Nausea, vomiting, retching and PONV (cumulative) will be
      recorded immediately after extubation and six hourly thereafter for the first 24 hours. Pain
      scores assessed by VAS (verbal analogue scale) will be recorded at the same time points.
      Also, if patients received fluids and solid food by mouth.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">February 17, 2017</start_date>
  <completion_date type="Anticipated">December 16, 2018</completion_date>
  <primary_completion_date type="Anticipated">December 16, 2018</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>PONV (postoperative nausea vomiting)</measure>
    <time_frame>24 hours</time_frame>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">115</enrollment>
  <condition>Postoperative Nausea and Vomiting</condition>
  <arm_group>
    <arm_group_label>preemptive group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>The preemptive group will receive the anti-emetic regimen i.v. (10 mg of metoclopramide at 18 pm and 22 pm, and100 mg of dimenhydrinate at 22 pm) the day before surgery. During surgery this group will receive i.v. 0.9% NaCl in volumes equal to the volume of 10 mg of metoclopramide before anesthesia induction and 30 min after skin incision. Thirty minutes after skin incision 0.9% NaCl equal in volume with the volume of 100 mg dimenhydrinate will be given as well.
The intervention consists of the different time points of antiemetic treatment, thus the day before surgery.
Intervention: Antiemetic treatment the day before surgery</description>
  </arm_group>
  <arm_group>
    <arm_group_label>intraoperative group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>The day before surgery the intraoperative group will receive i.v. 0.9% NaCl at 18 pm and 22 pm in volumes equal to the volume of 10 mg of metoclopramide; also 0.9% NaCl in volume equal to the volume of 100 mg dimenhydrinate at 22 pm will be given. During surgery the active comparator group will receive i.v. 10 mg of metoclopramide and 100 mg of dimenhydrinate instead of NaCl at the same time points as the preemptive group.
Intervention: Antiemetic treatment intraoperatively</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Antiemetic treatment the day before surgery vs intraoperatively</intervention_name>
    <description>Preemptive group The antiemetic regime thus 2 doses of 10 mg each metoclopramide will be administered the day before surgery Intraoperative group The antiemetic regime thus 2 doses of 10 mg each metoclopramide will be administered intraoperatively</description>
    <arm_group_label>preemptive group</arm_group_label>
    <arm_group_label>intraoperative group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  ASA physical status I-II patients

          -  Surgical procedure: scheduled for thyroidectomy

          -  Type of anesthesia: general

        Exclusion Criteria:

          -  Antihistamines the last three days

          -  Antiemetic drugs the last three days

          -  Hiatus hernia

          -  Gastrointestinal disease

          -  Pregnancy

          -  BMI &gt; 35.
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Argyro Fassoulaki, MD PhD DEAA</last_name>
    <phone>306936701333</phone>
    <email>afassou1@otenet.gr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Aimilia Vassi, MD PhD</last_name>
    <phone>306938691476</phone>
    <email>applevass@yahoo.gr</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>St Savvas Hospital</name>
      <address>
        <city>Athens</city>
        <state>Attika</state>
        <zip>11522</zip>
        <country>Greece</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Argyro Fassoulaki, MD PhD DEAA</last_name>
      <phone>306936701333</phone>
      <email>fassoula@aretaieio.uoa.gr</email>
    </contact>
    <contact_backup>
      <last_name>Aimilia Vassi, MD PhD</last_name>
      <phone>306938691476</phone>
      <email>applevass@yahoo.gr</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>Greece</country>
  </location_countries>
  <reference>
    <citation>Odom-Forren J, Rayens MK, Gokun Y, Jalota L, Radke O, Hooper V, Wiggins AT, Apfel CC. The Relationship of Pain and Nausea in Postoperative Patients for 1 Week After Ambulatory Surgery. Clin J Pain. 2015 Oct;31(10):845-51. doi: 10.1097/AJP.0000000000000170.</citation>
    <PMID>25370136</PMID>
  </reference>
  <reference>
    <citation>Gan TJ, Diemunsch P, Habib AS, Kovac A, Kranke P, Meyer TA, Watcha M, Chung F, Angus S, Apfel CC, Bergese SD, Candiotti KA, Chan MT, Davis PJ, Hooper VD, Lagoo-Deenadayalan S, Myles P, Nezat G, Philip BK, Tramèr MR; Society for Ambulatory Anesthesia. Consensus guidelines for the management of postoperative nausea and vomiting. Anesth Analg. 2014 Jan;118(1):85-113. doi: 10.1213/ANE.0000000000000002. Erratum in: Anesth Analg. 2015 Feb;120(2):494. Anesth Analg. 2014 Mar;118(3):689.</citation>
    <PMID>24356162</PMID>
  </reference>
  <reference>
    <citation>Apfel CC, Heidrich FM, Jukar-Rao S, Jalota L, Hornuss C, Whelan RP, Zhang K, Cakmakkaya OS. Evidence-based analysis of risk factors for postoperative nausea and vomiting. Br J Anaesth. 2012 Nov;109(5):742-53. doi: 10.1093/bja/aes276. Epub 2012 Oct 3.</citation>
    <PMID>23035051</PMID>
  </reference>
  <reference>
    <citation>Apfel CC, Meyer A, Orhan-Sungur M, Jalota L, Whelan RP, Jukar-Rao S. Supplemental intravenous crystalloids for the prevention of postoperative nausea and vomiting: quantitative review. Br J Anaesth. 2012 Jun;108(6):893-902. doi: 10.1093/bja/aes138. Review.</citation>
    <PMID>22593126</PMID>
  </reference>
  <reference>
    <citation>Walldén J, Flodin J, Hultin M. Validation of a prediction model for post-discharge nausea and vomiting after general anaesthesia in a cohort of Swedish ambulatory surgery patients. Eur J Anaesthesiol. 2016 Oct;33(10):743-9. doi: 10.1097/EJA.0000000000000473.</citation>
    <PMID>27270883</PMID>
  </reference>
  <verification_date>February 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 13, 2017</study_first_submitted>
  <study_first_submitted_qc>January 13, 2017</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 18, 2017</study_first_posted>
  <last_update_submitted>February 21, 2017</last_update_submitted>
  <last_update_submitted_qc>February 21, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">February 23, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Athens</investigator_affiliation>
    <investigator_full_name>Argyro Fassoulaki</investigator_full_name>
    <investigator_title>Professor Emeritus</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vomiting</mesh_term>
    <mesh_term>Postoperative Nausea and Vomiting</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Metoclopramide</mesh_term>
    <mesh_term>Antiemetics</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

